IP Library › Granted Patent US 10,961,316
Granted Patent B2
US 10,961,316 · App. 16/538,526 · Granted Mar 30, 2021

Humanized antibodies which bind to human APRIL (“a proliferation-inducing ligand”)

Inventors: Hans van Eenennaam (Nijmegen, NL); Andrea van Elsas (Oss, NL); David Lutje Hulsik (Nijmegen, NL); Jan Paul Medema (Nieuw Vennep, NL)
Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
C07K16/2875A61K39/3955A61K45/06G01N33/564G01N33/57488A61K2039/505C07K2317/24C07K2317/30C07K2317/33C07K2317/56C07K2317/565C07K2317/567C07K2317/76C07K2317/92C07K2317/94G01N2800/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,961,316
App. No.
16/538,526
Granted
Mar 30, 2021
Kind
B2
Abstract

The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the V H and V L domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.

Claims (5)

1. A humanized antibody having (i) light chain complementary determining regions of SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, (ii), heavy chain complementary determining regions of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, and framework regions having at least 90% sequence similarity to the framework regions of SEQ ID NO: 50 and SEQ ID NO: 52, wherein the antibody binds to human “A proliferation-inducing ligand” (“APRIL”) protein.

2. A humanized antibody having a light chain of SEQ ID NO: 50 and a heavy chain of SEQ ID NO: 52.

3. A humanized antibody according to claim 1 , wherein at least 90% sequence similarity is at least 90% sequence identity.

4. A humanized antibody according to claim 1 , wherein at least 90% sequence similarity is at least 95% sequence similarity.

5. A humanized antibody according to claim 4 , wherein at least 95% sequence similarity is at least 95% sequence identity.

Priority Claims (1)
NL 2014108 · Jan 9, 2015 · national
Continuity (3)
Continuation 15978699 · May 14, 2018
Division 14991708 · Jan 8, 2016
Related Publication 20200079859A1 · Mar 12, 2020
Cited By (4)
US 12,202,882 US 12,304,943 US 12,612,446 US 12,612,447